Catalyst Biosciences Inks $7M from Phizer

4 years ago

Catalyst Biosciences Inc. has sealed a $7 million milestone payment from Pfizer, as part of a research and license agreement between the two companies. Catalyst recently initiated Phase 1 clinical trials for one of its products, designed to help treat hemophilia patients. Privately held Catalyst is backed by investors including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures.